Rani Therapeutics Holdings, Inc. financial data

Symbol
RANI on Nasdaq
Industry
Pharmaceutical Preparations
Location
2051 Ringwood Avenue, San Jose, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 414 % -74.2%
Debt-to-equity 357 % +280%
Return On Equity -152 % -199%
Return On Assets -54.2 % -56.1%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 54.1M USD -57.8%
Weighted Average Number of Shares Outstanding, Basic 26.3M shares +3.86%
Weighted Average Number of Shares Outstanding, Diluted 26.3M shares +3.86%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 32.5M USD -19.3%
General and Administrative Expense 25.3M USD -10.7%
Operating Income (Loss) -57.8M USD +15.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -67.9M USD -7.28%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -30.6M USD +11.1%
Earnings Per Share, Basic -1.18 USD/shares +54.3%
Earnings Per Share, Diluted -1.18 USD/shares +54.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.51M USD -40.2%
Marketable Securities, Current 98.5M USD
Assets, Current 32M USD -58.1%
Property, Plant and Equipment, Net 5.7M USD -4.11%
Operating Lease, Right-of-Use Asset 5.75M USD +382%
Other Assets, Noncurrent 246K USD
Assets 43.7M USD -47.6%
Accounts Payable, Current 506K USD -51.2%
Accrued Liabilities, Current 2.3M USD +60.1%
Liabilities, Current 16.6M USD +189%
Operating Lease, Liability, Noncurrent 4.39M USD +1198%
Liabilities 38.2M USD +8.03%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5K USD +92.1%
Retained Earnings (Accumulated Deficit) -87.2M USD -54%
Stockholders' Equity Attributable to Parent 2.84M USD -88.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.55M USD -88.5%
Liabilities and Equity 43.7M USD -47.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.4M USD +22.6%
Net Cash Provided by (Used in) Financing Activities 121K USD +1413%
Net Cash Provided by (Used in) Investing Activities 10.3M USD +150%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.01M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.01M USD -37.7%
Deferred Tax Assets, Valuation Allowance 61M USD +15.5%
Deferred Tax Assets, Gross 61M USD +15.5%
Operating Lease, Liability 5.75M USD +382%
Depreciation 111K USD -18.4%
Payments to Acquire Property, Plant, and Equipment 18K USD -92.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30.5M USD +11.5%
Lessee, Operating Lease, Liability, to be Paid 7.13M USD +460%
Property, Plant and Equipment, Gross 5.87M USD +31.3%
Operating Lease, Liability, Current 1.36M USD +59.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.9M USD +264%
Lessee, Operating Lease, Liability, to be Paid, Year One 930K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.38M USD +1664%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.23M USD +64.1%
Deferred Tax Assets, Operating Loss Carryforwards 13M USD +90.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 489K USD +132%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.28M USD
Operating Lease, Payments 180K USD -30.5%
Additional Paid in Capital 90M USD +11.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 18.9M USD +1.07%
Share-based Payment Arrangement, Expense 15.8M USD -30.2%
Interest Expense 5.18M USD +46.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%